Topoisomerase I inhibitors: selectivity and cellular resistance

被引:157
作者
Pommier, Y [1 ]
Pourquier, P [1 ]
Urasaki, Y [1 ]
Wu, JX [1 ]
Laco, GS [1 ]
机构
[1] NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1054/drup.1999.0102
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Topoisomerase I (top I)inhibitors (camptothecins and other structurally diverse compounds) are effective and promising anticancer agents. Determinants of selectivity toward cancer cells and resistance are multifactorial. These factors can be separated in three groups. The first is related to alterations in drug distribution and metabolism. The second group includes both quantitative and qualitative (mutations) differences in top I. The third group includes resistance and sensitivity factors downstream from the cleavage complexes. They include DNA repair, cell cycle checkpoints and apoptosis, and are probably key to the relative selectivity of camptothecins toward cancer cells and to clinical resistance.
引用
收藏
页码:307 / 318
页数:12
相关论文
共 119 条
[1]   PARTIAL-PURIFICATION AND RECONSTITUTION OF THE HUMAN MULTIDRUG-RESISTANCE PUMP - CHARACTERIZATION OF THE DRUG-STIMULATABLE ATP HYDROLYSIS [J].
AMBUDKAR, SV ;
LELONG, IH ;
ZHANG, JP ;
CARDARELLI, CO ;
GOTTESMAN, MM ;
PASTAN, I .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (18) :8472-8476
[2]   CHARACTERIZATION OF A MAMMALIAN MUTANT WITH A CAMPTOTHECIN-RESISTANT DNA TOPOISOMERASE-I [J].
ANDOH, T ;
ISHII, K ;
SUZUKI, Y ;
IKEGAMI, Y ;
KUSUNOKI, Y ;
TAKEMOTO, Y ;
OKADA, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (16) :5565-5569
[3]  
Bailly C, 1999, CANCER RES, V59, P2853
[4]   DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin [J].
Bailly, C ;
Riou, JF ;
Colson, P ;
Houssier, C ;
RodriguesPereira, E ;
Prudhomme, M .
BIOCHEMISTRY, 1997, 36 (13) :3917-3929
[5]   The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication [J].
Barrows, LR ;
Holden, JA ;
Anderson, M ;
D'Arpa, P .
MUTATION RESEARCH-DNA REPAIR, 1998, 408 (02) :103-110
[6]  
Beidler DR, 1996, CANCER RES, V56, P345
[7]  
BEIDLER DR, 1995, MOL PHARMACOL, V47, P907
[8]  
BENEDETTI P, 1993, CANCER RES, V53, P4343
[9]   Analysis of camptothecin resistance in yeast: relevance to cancer therapy [J].
Benedetti, P ;
Benchokroun, Y ;
Houghton, PJ ;
Bjornsti, MA .
DRUG RESISTANCE UPDATES, 1998, 1 (03) :176-183
[10]   Identification of a nucleolin binding site in human topoisomerase I [J].
Bharti, AK ;
Olson, MOJ ;
Kufe, DW ;
Rubin, EH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (04) :1993-1997